Fennec Pharmaceuticals Inc (FENC) Stock Price, Quote & News

Company Profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 636 4530

Website: fennecpharma.com

Address:

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, United States

William_55555 Aug. 3 at 12:34 AM

$FENC this management team is terrible. Expect lots of pain, unless your short then nothing but sunshine and rainbows

0 · Reply

Night_Owl_Biotech Jul. 29 at 8:48 PM

Commercial-stage oncology focused bios that sell within 2 years of FDA approval deliver the best returns in the peer group (versus share prices as of FDA approval). 14 of the 16 oncology focused bios that sold at meaningful gains were sold within 2 years. 7 of the 8 that sold at large losses (excl 3 that went bankrupt) waited for more than 2 years to sell. Attached is a list of all new comm'l-stage oncology focused bios since 1/1/2020 (excl. ONC). History suggests those with 1st approvals within the last year are most likely to exit via M&A at gains. Of course times change & we could be proven wrong in the future. If we had to guess, and that's all it is, we'd guess the bios in green are most likely to sell within the next 12 months. This is for entertainment purposes only. There is zero chance we will be 100% right $URGN (with recent 2nd approval) $AUTL $ZYME $FENC (they've been trying to sell for years) & $LEGN Of the 35 still independent, only 7 trade higher today.

3 · Reply

William_55555 Jul. 11 at 11:14 PM

$FENC haha couldnt hold $9.00 nice try Jack

0 · Reply

JackCampbell Jul. 11 at 12:55 PM

$FENC come on, give us double digits!

0 · Reply

JackCampbell Jul. 3 at 3:35 PM

$FENC New 52 weeks high reached today!

2 · Reply

Doozio Jun. 27 at 2:42 AM

$FENC during 🐒🍌🧠⏰♾️

0 · Reply

JackCampbell Jun. 24 at 6:54 PM

$FENC impressive bullish chart here!!!

0 · Reply

jumhoura1 Jun. 24 at 6:34 PM

$FENC let’s get to double digits 💪🏻 finally turning around as a company

0 · Reply

William_55555 Jun. 18 at 7:21 PM

$FENC watch out everyone. This company is BAD

0 · Reply

StockSamL Jun. 18 at 7:50 AM

$BPMC $VSTM $IBRX $GERN $FENC

1 · Reply

Fennec Announces Results of Annual Meeting

May 13, 2025, 12:23 PM EDT - 2 months ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:17 PM EDT - 3 months ago

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Mar 10, 2025, 10:24 AM EDT - 5 months ago

Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 6:03 AM EDT - 5 months ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 4:22 PM EST - 5 months ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Feb 7, 2025, 7:00 AM EST - 6 months ago

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Dec 20, 2024, 6:16 AM EST - 8 months ago

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Dec 19, 2024, 6:13 AM EST - 8 months ago

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Dec 12, 2024, 7:01 AM EST - 8 months ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Nov 9, 2024, 10:33 PM EST - 9 months ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:13 AM EST - 9 months ago

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 31, 2024, 6:23 AM EDT - 9 months ago

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 28, 2024, 6:23 AM EDT - 9 months ago

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Sep 5, 2024, 6:56 AM EDT - 11 months ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2024, 2:20 PM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 6:05 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:31 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Aug 5, 2024, 6:26 AM EDT - 1 year ago

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Announces Management Change

May 14, 2024, 1:15 PM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:03 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 6:15 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Mar 21, 2024, 12:30 PM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Mar 19, 2024, 6:01 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Mar 17, 2024, 9:00 PM EDT - 1 year ago

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Mar 6, 2024, 8:39 PM EST - 1 year ago

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price

Feb 29, 2024, 7:04 AM EST - 1 year ago

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Feb 1, 2024, 5:55 AM EST - 1 year ago

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Dec 5, 2023, 5:55 AM EST - 1 year ago

Fennec Announces Incremental $5 Million Investment from Petrichor

Nov 9, 2023, 6:24 PM EST - 1 year ago

Fennec Pharmaceuticals Expands Possible TAM Significantly

Nov 6, 2023, 11:19 AM EST - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 5:59 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 6:45 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Aug 6, 2023, 9:00 AM EDT - 2 years ago

Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 5:59 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 31, 2023, 5:30 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Jun 6, 2023, 5:44 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

May 13, 2023, 11:34 PM EDT - 2 years ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript

May 11, 2023, 6:01 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023, 6:15 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Apr 26, 2023, 8:33 AM EDT - 2 years ago

Fennec Pharmaceuticals: Undervalued, Near-Cash-Flow-Positive, Possible Buyout Candidate

Apr 5, 2023, 8:43 AM EDT - 2 years ago

Fennec Pharmaceuticals Gains Momentum With Industry Endorsements

Mar 31, 2023, 8:03 AM EDT - 2 years ago

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Mar 30, 2023, 5:55 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Jan 31, 2023, 6:00 AM EST - 2 years ago

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

Jan 25, 2023, 7:19 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

Jan 16, 2023, 5:45 AM EST - 2 years ago

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale

Nov 11, 2022, 7:10 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

William_55555 Aug. 3 at 12:34 AM

$FENC this management team is terrible. Expect lots of pain, unless your short then nothing but sunshine and rainbows

0 · Reply

Night_Owl_Biotech Jul. 29 at 8:48 PM

3 · Reply

William_55555 Jul. 11 at 11:14 PM

$FENC haha couldnt hold $9.00 nice try Jack

0 · Reply

JackCampbell Jul. 11 at 12:55 PM

$FENC come on, give us double digits!

0 · Reply

JackCampbell Jul. 3 at 3:35 PM

$FENC New 52 weeks high reached today!

2 · Reply

Doozio Jun. 27 at 2:42 AM

$FENC during 🐒🍌🧠⏰♾️

0 · Reply

JackCampbell Jun. 24 at 6:54 PM

$FENC impressive bullish chart here!!!

0 · Reply

jumhoura1 Jun. 24 at 6:34 PM

$FENC let’s get to double digits 💪🏻 finally turning around as a company

0 · Reply

William_55555 Jun. 18 at 7:21 PM

$FENC watch out everyone. This company is BAD

0 · Reply

StockSamL Jun. 18 at 7:50 AM

$BPMC $VSTM $IBRX $GERN $FENC

1 · Reply

JackCampbell Jun. 7 at 12:46 PM

$FENC fully on track, double digits in sight!

0 · Reply

MF__THUUM Jun. 3 at 1:55 PM

$FENC order executed for a loss. Will see what it looks like at noon before thinking of a reentry

0 · Reply

MF__THUUM Jun. 3 at 1:07 PM

$FENC 7.80 stop loss, better start strong this morning FENC!

0 · Reply

Night_Owl_Biotech Jun. 3 at 1:00 AM

Attached is our updated table of what's happened to the share price, of all 60 publicly-held bios that received their 1st FDA approval for a cancer related therapy back to 1/1/2013, since FDA approval. 16 of the 60 were acquired at meaningful gains versus their share price at FDA approval. Of these 16, 14 were acquired within 2 years of FDA approval. Of the 2 outliers, TSRO was acquired within 2 years of Zejula's approval. Zejula was always Tesaro's flagship. Even $BPMC was acquired within 2 years of Ayvakit's ISM label expansion. 8 of the 60 were sold at meaningful losses. 7 of the 8 waited for over 2 years to sell. 3 of the 60 went bankrupt or were delisted. Of the 33 independent, roughly 9 of 10 trade lower (and most much lower). Include BPMC or not, the odds are overwhelming commercial-stage oncology focused bio shareholders are best served via M&A within 2 years of approval. $VSTM $IBRX $GERN $FENC

9 · Reply

Night_Owl_Biotech May. 31 at 7:38 PM

Attached is a schedule of all commercial-stage oncology focused bio share price changes since the XBI's recent low on 4/8/2025 (during the tariff market event) for all peers with a market cap north of $200MM as of 5/30/25 versus the $XBI. $ADCT is overwhelmingly the best performer. We have no interest in @keypatience but he called it. Read his posts from around early April $FENC has surged but has been for sale for years. $IMCR has not traded for north of $35 since early September 2024 after coming down from $75 in Feb. 2024. Gains have been very recent. We're unaware of any IMCR news the last 2 weeks. $AUTL still trades for less than cash after an impressive Q1 25 beat. Aucatzyl is expected to take major share from Tecartus in AML. This is not investment advice.

2 · Reply

JackCampbell May. 30 at 8:24 PM

$FENC post of a clown deep underwater. You’ll be wrong all the way up, below $7 this week 🤣🤣🤣👇👇👇

0 · Reply

William_55555 May. 24 at 5:52 PM

$FENC watch for under $7 this week. Bad management. Fake drug that can be compounded for $1

1 · Reply

Eaglelanded May. 22 at 7:27 PM

$FENC moron below👇🏻

0 · Reply

William_55555 May. 21 at 6:46 PM

$FENC anemic growth again. CEO making big promises and then purchase very small $100K of stock. Dont fall for the trap. What matters is growth, and its non existent. Sales this quarter were LOWER than Q4 2023.... FACT

0 · Reply

JackCampbell May. 21 at 8:49 AM

$FENC Mr. Hackman has served as director of Fennec Pharmaceuticals and Chief Executive Officer since August 2024. Mr. Hackman, age 62, brings more than 30 years of commercial leadership experience to the Company, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. His tenure in oncology spans the last 12 years across Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he was responsible for the U.S. commercial organizations and managing respective product portfolios in multiple franchises, which generated billions in revenue over the years. More specifically, Mr. Hackman has successfully commercialized products that are specifically relevant to the PEDMARK® markets, including the outpatient oncology community and the AYA population.

0 · Reply

PenkeTrading May. 20 at 2:22 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Fennec Pharmaceuticals Inc. Is that bullish or bearish? $FENC #Fennec #RsiOverbought #NASDAQ

0 · Reply

JarvisFlow May. 20 at 11:00 AM

HC Wainwright & Co. updates rating for Fennec Pharmaceuticals ( $FENC ) to Buy, target set at 13.

0 · Reply

Market Cap	217.43M
Revenue (ttm)	47.54M
Net Income (ttm)	-440,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	53.35
Profit Margin	-0.93%
Debt to Equity Ratio	-3.07

Volume	54,800
Avg Vol	76,310
Day's Range	N/A - N/A
Shares Out	27.73M
Stochastic %K	0%
Beta	0.40
Analysts	Strong Sell
Price Target	$12.80